Literature DB >> 25953975

Ph+ ALL: drawing strength from a benign past.

Markus Müschen1.   

Abstract

In this issue of Blood, Mallampati et al report on the discovery of a new mechanism of tyrosine kinase inhibitor (TKI) resistance, which is mediated through TKI-mediated priming of mesenchymal stem cells (MSCs) in the bone marrow (BM).

Mesh：

Substances：

Year:  2015        PMID： 25953975      PMCID： PMC4424411          DOI： 10.1182/blood-2015-03-632174

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  10 in total

1.  Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.

Authors:  Bin Zhang; Min Li; Tinisha McDonald; Tessa L Holyoake; Randall T Moon; Dario Campana; Leonard Shultz; Ravi Bhatia
Journal:  Blood       Date:  2013-01-08       Impact factor: 22.113

2.  Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms.

Authors:  Lorena Arranz; Abel Sánchez-Aguilera; Daniel Martín-Pérez; Joan Isern; Xavier Langa; Alexandar Tzankov; Pontus Lundberg; Sandra Muntión; Yi-Shiuan Tzeng; Dar-Ming Lai; Jürg Schwaller; Radek C Skoda; Simón Méndez-Ferrer
Journal:  Nature       Date:  2014-06-22       Impact factor: 49.962

3.  Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.

Authors:  Shotaro Iwamoto; Keichiro Mihara; James R Downing; Ching-Hon Pui; Dario Campana
Journal:  J Clin Invest       Date:  2007-03-22       Impact factor: 14.808

4.  Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.

Authors:  Suparna Mishra; Bin Zhang; Jess M Cunnick; Nora Heisterkamp; John Groffen
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

5.  Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.

Authors:  Saradhi Mallampati; Xiaohong Leng; Haiqing Ma; Jianfang Zeng; June Li; Haiying Wang; Kevin Lin; Yue Lu; Yang Yang; Baohua Sun; Yun Gong; Ju-Seog Lee; Marina Konopleva; Michael Andreeff; Ralph B Arlinghaus; Zhen Cai; Bingliang Fang; Haifa Shen; Xin Han; Cheryl F Hirsch-Ginsberg; Xiaolian Gao; Anurag N Paranjape; Sendurai A Mani; Karen Clise-Dwyer; Xiaoping Sun
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

6.  Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.

Authors:  Iris Appelmann; Cory D Rillahan; Elisa de Stanchina; Gregory Carbonetti; Chong Chen; Scott W Lowe; Charles J Sherr
Journal:  Blood       Date:  2014-12-12       Impact factor: 22.113

7.  Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.

Authors:  Pablo Menendez; Purificación Catalina; René Rodríguez; Gustavo J Melen; Clara Bueno; Mar Arriero; Félix García-Sánchez; Alvaro Lassaletta; Ramón García-Sanz; Javier García-Castro
Journal:  J Exp Med       Date:  2009-12-07       Impact factor: 14.307

8.  Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

Authors:  Hind Medyouf; Maximilian Mossner; Johann-Christoph Jann; Florian Nolte; Simon Raffel; Carl Herrmann; Amelie Lier; Christian Eisen; Verena Nowak; Bettina Zens; Katja Müdder; Corinna Klein; Julia Obländer; Stephanie Fey; Jovita Vogler; Alice Fabarius; Eva Riedl; Henning Roehl; Alexander Kohlmann; Marita Staller; Claudia Haferlach; Nadine Müller; Thilo John; Uwe Platzbecker; Georgia Metzgeroth; Wolf-Karsten Hofmann; Andreas Trumpp; Daniel Nowak
Journal:  Cell Stem Cell       Date:  2014-04-03       Impact factor: 24.633

9.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.

Authors:  Cihangir Duy; Christian Hurtz; Seyedmehdi Shojaee; Leandro Cerchietti; Huimin Geng; Srividya Swaminathan; Lars Klemm; Soo-mi Kweon; Rahul Nahar; Melanie Braig; Eugene Park; Yong-mi Kim; Wolf-Karsten Hofmann; Sebastian Herzog; Hassan Jumaa; H Phillip Koeffler; J Jessica Yu; Nora Heisterkamp; Thomas G Graeber; Hong Wu; B Hilda Ye; Ari Melnick; Markus Müschen
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

10.  Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts.

Authors:  Aruna Kode; John S Manavalan; Ioanna Mosialou; Govind Bhagat; Chozha V Rathinam; Na Luo; Hossein Khiabanian; Albert Lee; Vundavalli V Murty; Richard Friedman; Andrea Brum; David Park; Naomi Galili; Siddhartha Mukherjee; Julie Teruya-Feldstein; Azra Raza; Raul Rabadan; Ellin Berman; Stavroula Kousteni
Journal:  Nature       Date:  2014-01-15       Impact factor: 49.962
  10 in total
  1 in total

1.  The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.

Authors:  Yi Ru; Qinhao Wang; Xiping Liu; Mei Zhang; Daixing Zhong; Mingxiang Ye; Yuanchun Li; Hua Han; Libo Yao; Xia Li
Journal:  Sci Rep       Date:  2016-06-22       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.